Message from the Chairman

About Duke-NUS Medical School

Innovating in Education

Fostering an Entrepreneurial Spirit

A Winning Collaboration in Academic Medicine

Giving to Duke-NUS

Message from the Dean

Making a Difference Through Research
MESSAGE FROM THE CHAIRMAN
2017 marked the start of the third phase of the partnership between Duke University and the National University of Singapore. Born out of a strategic vision to transform medicine and improve lives, Duke-NUS continues to nurture clinical innovators and translates discovery into better health.

Duke-NUS’ Academic Medicine partnership with Singapore’s largest healthcare cluster, Singapore Health Services (SingHealth) has flourished and is scaling new heights. Our faculty has been very successful in securing competitive funding to support their research, including prestigious open-fund, large, collaborative grants, enabling our pursuit of translational research discoveries that can benefit patients in Singapore and beyond.

Our distinguished educators are continuing to promote a culture of curiosity and inquiry, nurturing our students with a “Clinician Plus” distinction. Our Doctor of Medicine (MD) programme attracts talented students from diverse academic and national backgrounds. Our multidisciplinary PhD programmes in Integrated Biology and Medicine, Integrated Biostatistics and Bioinformatics and Clinical Sciences are aimed at further advancing biomedical science and translational bioscience by leveraging data analytics and advanced statistical innovation. Improved patient-oriented research and strengthened industry collaborations will help us contribute towards Singapore’s goal of becoming a world-class biomedical hub.

It has been another year of great achievements and successes. I take this opportunity to thank our key stakeholders – the Ministry of Education, the Ministry of Health, SingHealth, Duke University and the National University of Singapore among many others, the School’s senior leadership team and members of the School’s Governing Board for their continued support, dedication and professionalism. I especially thank our donors, who had given generously to Duke-NUS, enabling us to continue to pursue our mission to educate, inspire and innovate.

Kai Nargolwala
Chairman, Governing Board
We are very pleased to unveil our inaugural Duke-NUS Medical School Annual Review. Thirteen years ago, Duke-NUS was established as Singapore’s first graduate-entry medical school. Since then, our School has been a disruptive force in the local medical education and research landscapes, training outstanding clinicians with the passion, skills and know-how to meet the evolving challenges in healthcare today. This annual review serves to document our accomplishments during the past academic year, highlighting some of our most important milestones.

We continue to admit and educate highly qualified students with diverse interests and backgrounds. This year, adding to our existing partnerships with Duke University and the Faculty of Engineering at NUS, we launched new through-train, conditional admissions pathways with Yale-NUS College and the Singapore University of Technology and Design. Our education team has also revised and refreshed our curriculum with innovative approaches to clinical training that will be launched this summer, helping prepare our graduates for post-graduate training, imbuing them with the skills and perspectives for transforming medicine and improving lives.

As a part of our commitment to enhancing medical practice across Singapore, we have launched a new PhD Programme in Clinical Sciences, targeting clinicians in post-graduate training who are interested in pursuing careers in research.

Our research programmes have also excelled in the past year. A few of our recent research highlights include discovery of the critical role of interleukin 11 in the process of organ fibrosis, identification of the essential role of DHA in foetal brain development and Duke-NUS investigators leading the fight against Dengue and Zika viruses. These breakthroughs not only pave the way for novel treatments, vaccines and nutritionals but also have substantial commercial potential, leading to the establishment of four spin-off companies. Since 2013, Duke-NUS’ investigators have successfully obtained 48 patents and have been involved in 14 spin-off companies, facilitated by our Centre for Technology and Development.
Our partnership with SingHealth is a key component of all of our School’s programmes. The SingHealth Duke-NUS Academic Medical Centre (AMC) provides an outstanding environment for clinical training and for translating research discoveries to help patients. Over the past year, we have revamped our office structure to help enhance academic medicine programmes and provide more recognition and support for SingHealth clinicians on our faculty who provide superb clinical education for our students. We also launched a new Academic Clinical Programme (ACP) in Emergency Medicine. We now have 15 ACPs spanning the major medical specialities, providing academic connections between clinical units at SingHealth and Duke-NUS.

Our AMC also provides an outstanding framework for research collaborations between basic and clinical researchers, and this year, a team comprising investigators from Duke-NUS and the National Cancer Centre of Singapore (NCCS) became the first Asian team to win the prestigious American Association for Cancer Research Team Science Award.

The achievements highlighted in this report make up a mere fraction of our accomplishments, and it was difficult to choose just a few to feature here. These accomplishments are possible because of the hard work and dedication of our faculty and staff, with generous backing from our philanthropic supporters. These donors have been crucial in promoting innovative and life-saving research, allowing our students to pursue medicine without financial burden, and amplifying our School’s impact in Singapore and beyond.

I am very proud of the great things our faculty, staff, alumni and students have accomplished together, as described in the following pages. With your continuing support, I look forward to many more transformative accomplishments in the years ahead.

Professor Thomas M. Coffman
Dean

We continue to admit and educate highly qualified students with diverse interests and backgrounds.
<table>
<thead>
<tr>
<th>Established In</th>
<th>First Intake In</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2005</strong></td>
<td><strong>2007</strong></td>
</tr>
</tbody>
</table>

- 85 students had masters degrees before admission to Duke-NUS
- 33 students had PhDs before admission to Duke-NUS
- 378 students have graduated with a MD degree since 2011
- 6 students have filed patents as a result of their research projects
Duke-NUS Medical School (Duke-NUS) is a partnership established in 2005 between Duke University and the National University of Singapore. A pioneering innovator in medical education, we are positioned to meet the changing medical landscape and the future healthcare needs of Singapore.

We offer a four-year programme based on the curriculum of the Duke University School of Medicine with an integrated approach that combines academic learning, strong clinical training and critical thinking skills. Our diverse student body comprises outstanding local and international graduate-entry students from a breadth of academic disciplines, whose combined experiences contribute to advancing medical science.

As a research-centric medical school, Duke-NUS boasts leading research capabilities as well as scientists at the forefront of their fields. Our students, learning alongside these scientists, are well poised to ask critical questions and explore theories that can impact the way diseases are identified and treated. Our cutting-edge signature research programmes spanning basic, translational and clinical research aim to make a substantive impact on Singapore's biomedical sciences landscape.

Our vibrant and dynamic ecosystem in Academic Medicine, created in partnership with SingHealth, positions us well to transform medicine through our integrated expertise in clinical care, education and research.
COURAGE
Our mission is to nurture individuals from diverse backgrounds to be outstanding clinicians, capable of becoming future leaders, educators, scholars and scientists in healthcare, while serving the needs of Singapore and beyond with compassion and excellence.

Students enter with at least a Bachelor’s degree in any field, and graduate with a joint degree from Duke University and NUS. Currently, we offer a Doctor of Medicine (MD) programme, Doctor of Philosophy (PhD) programmes and a combined track (MD-PhD) to prepare them for careers in medicine and research.
An Innovative Approach to Learning

Our students benefit from our TeamLEAD (Learn, Engage, Apply and Develop) methodology, which we have implemented across the entire preclinical education curriculum. Each facilitator-directed classroom session offers a supportive environment where students can discuss and share their findings in groups.

The Duke-NUS Clinician plus philosophy aims to develop well-rounded and high-performing individuals who can contribute to society beyond their medical expertise. Our students are given opportunities to pursue research and scholarships as well as exposure to innovation and design thinking.

They enjoy a stimulating and holistic experience at Duke-NUS, ensuring that their time with us is not just rewarding academically, but also fulfilling and enriching socially. Students are assigned to one of four advisory colleges: Gordon Arthur Ransome College, Seah Cheng Siang College, Benjamin Sheares College and Eugene Stead College - each named after a legendary figure in medicine. Here, the students receive support and mentorship from their peers and seniors.

Beyond the classroom, they actively participate in community projects to hone their social skills and add a real-world perspective to what they learn.

New Pathways, Centres & Institutes

A New Pathway Between Duke-NUS and Yale-NUS
Liberal arts students now have a new pathway to pursue medicine, with a new joint initiative between Duke-NUS and Yale-NUS College. This pathway aims to shape future clinicians who appreciate the interconnectedness of sciences, social sciences and humanities in medical practice.

New Institute to Tackle Global Health Challenges in the Region
A new SingHealth Duke-NUS Global Health Institute (SDGHI) was launched to address global health challenges in South East Asia and the region. The Institute will look at achieving health equity through research, education, training and clinical practice. SDGHI allows collaboration between countries in the region and further afield to address health issues, strengthen health systems, and better insulate countries from pandemics and disease threats.

Dedicated Centre to Groom Clinician Scientists
A new Centre for Clinician-Scientist Development (CCSD) was developed under the Office of Research to further enhance the progression pathways for our Clinician Scientists. It focuses on mentoring efforts, provides personalised career guidance and organises structured training to nurture budding clinician scientists in improving their research and leadership skills.
Duke-NUS MD students have completed or been accepted to additional graduate degree programmes (as of 31 Aug 2018)

Undergraduate Major

- 18% Engineering
- 75% Sciences
- 5% Arts & Humanities
- 2% Business & Others

26.5%

173 of 652* Duke-NUS MD students have completed or been accepted to additional graduate degree programmes

*(as of 31 Aug 2018)
Showcasing A Few Firsts

First Asian Research Team Led by Duke-NUS Wins Prestigious AACR Team Science Award

For the first time, an Asian team of cancer researchers from Duke-NUS and the National Cancer Centre Singapore (NCCS) has won the prestigious American Association for Cancer Research (AACR) Team Science Award, which honours researchers for their global impact on cancer research. The team studied numerous cancers and helped to identify genes and pathways that may represent new avenues for further therapies.

First PhD Programme in Clinical Sciences

We have launched a first-of-its-kind PhD programme to create a pipeline of clinician scientists who will lead future biomedical research efforts in Singapore with the aim to improve patient outcomes and enhance Singapore’s international reputation in medical research.

First Asian-focused Graduate Certificate Programme in Pharmaceutical Regulation

Our Centre of Regulatory Excellence (CoRE) has launched its first Graduate Certificate Programme in Pharmaceutical Regulation. This is specifically tailored to address the needs of early and mid-career regulatory professionals in Singapore and the region.

First Neonatal Palliative Care Guide Book Launched to Equip Clinicians to Manage Vulnerable Babies

Duke-NUS’ Lien Centre for Palliative Care (LCPC) teamed up with three hospitals and a hospice centre to develop the first-ever guide book in Singapore to address the complex needs of vulnerable babies. This further equips healthcare clinicians with the knowledge and skills required to provide comfort care and support in managing such babies.
INTEGRITY
MAKING A DIFFERENCE THROUGH RESEARCH
Our Signature Research Programmes

With the vision to make a substantive impact on Singapore’s biomedical sciences scene, Duke-NUS has established five world-class Signature Research Programmes (SRPs), with each extending from fundamental or discovery science into the translational and clinical realm. We selected these research areas due to their relevance to major health burdens in Singapore and the region, and believe that there is a competitive advantage for conducting such research in Singapore, with the programmes capitalising on the strengths of Duke University. Our students will all be expected to complete their advanced training in one of these five SRPs.

Cancer & Stem Cell Biology
Scientists affiliated with the rapidly growing Cancer and Stem Cell Biology (CSCB) Programme study the causes and treatments of cancer and related diseases. Our research groups put special emphasis on the cancers that affect the Asian community in general. The CSCB Programme also builds collaborative networks with the existing cancer research community in Singapore, including the NCCS, NUS and A*STAR Research Institutes.

Cardiovascular & Metabolic Disorders
Diseases like hypertension, atherosclerosis and diabetes account for a disproportionately high percentage of healthcare costs, both in Singapore and across Asia. Our Outram campus, within close proximity of the National Heart Centre and the Diabetes and Metabolism Centre, presents a wealth of opportunities for translational and clinical research in cardiovascular and metabolic disorders (CVMD).

Emerging Infectious Diseases
One of the key goals of the Emerging Infectious Diseases (EID) Programme is to set up a world-class regional infectious disease centre for reference and research in the Asia-Pacific region. The purpose of this programme at Duke-NUS is to pioneer the development and discovery of new and more effective ways to treat, prevent and control new and emerging pathogens. This is aided by partner organisations like NUS, Tan Tock Seng Hospital, Singapore General Hospital, the A*STAR institutes, DSO National Laboratories and the Novartis Institute for Tropical Diseases.

Health Services & Systems Research
Health Services and Systems Research (HSSR) was established to bring the best in the field in health services research to Duke-NUS Medical School, SingHealth and Singapore. The objective is not only to cultivate world-class research capabilities, but also to improve patients’ lives in Singapore, regionally and internationally. In tandem with the other research programmes at Duke-NUS, HSSR has developed a rich portfolio of research projects and has established itself as the premier institute involved in health services research in Singapore.
The Neuroscience and Behavioural Disorders Programme (NBD) is focused on understanding the structure and function of the nervous system, and the neural mechanisms underlying human neurological, psychiatric and ophthalmological disorders. NBD actively collaborates with clinical faculties at Singapore General Hospital, National Neuroscience Institute (NNI), Institute of Mental Health and Singapore Eye Research Centre. The National Neuroscience Research Institute Singapore (NNRIS), a Singapore-wide initiative anchored by NNI and Duke-NUS, was launched to improve treatment and seek cures through research for brain and nervous system disorders.

*Duke-NUS faculty and faculty holding primary academic appointment at Duke-NUS.
Our Research Centres

Centre for Ageing, Research & Education (CARE) – an academic research centre that adopts a multidisciplinary approach towards research around ageing. Its mission is to provide translatable research evidence to support population ageing initiatives in Singapore and the region. CARE also spearheads educational programmes to build competencies on ageing among researchers, policymakers and programme professionals.

Centre for Computational Biology (CCB) – provides expertise in computational biology and bioinformatics. CCB investigators are especially adept at integrated analyses for omics studies and systems biology approaches.

Centre for Clinician Scientist Development (CCSD) – coordinates mentoring efforts, provides personalised career guidance and organises structured training to nurture budding clinician scientists as they improve their research and leadership skills.

Centre for Cognitive Neuroscience (CCN) – one of Duke-NUS’ pioneer labs, comprises several faculties engaged in multidisciplinary research into the neural underpinnings of human behaviour.

Centre of Regulatory Excellence (CoRE) – aims to support the fast-growing biomedical industry in the Asia-Pacific region through the promotion of regulatory leadership and policy innovation in science and scientific excellence.

Centre for Quantitative Medicine (CQM) – an academic home made up of quantitative scientists in the medical field. It serves as a point of contact for biomedical researchers from Duke-NUS’ partners requiring quantitative expertise.

Centre for Technology & Development (CTeD) – facilitates translation of research arising from the activities of Duke-NUS and its partners into commercial application. Its overarching goal is to establish sustainable, long-term relationships with external private and public partners to provide long-term value to Singapore’s biomedical research ecosystem.

Lien Centre for Palliative Care (LCPC) – the first of its kind in Asia. Its goal is to build a strong pool of palliative healthcare professionals to enhance service delivery through innovative training programmes and research.
NEW DISCOVERIES IN MEDICAL RESEARCH

IN RESEARCH FUNDING LOCALLY AND OVERSEAS

> $460 MILLION
Breakthrough Mouse Model for Diabetic Kidney Disease
Our scientists led a team that have bred mice that successfully emulate a severe form of kidney damage in humans with diabetes, called diabetic nephropathy. Genetic analyses of the mice led to the surprising finding that expression of genes controlling immune and inflammatory responses may play a causal role in promoting kidney damage, and suggest these pathways might be promising targets for therapy.

First System in the World to Cultivate Human Skin Cells for Grafting
Duke-NUS researchers scored a breakthrough research in using a specific type of tissue-proteins known as laminins, found in the human body, to create a safer treatment for severe burns or other skin-related defects.

Major Discovery - Critical Protein Found for Fibrosis Treatment
Researchers from Duke-NUS and the National Heart Centre Singapore (NHCS) made a breakthrough discovery of a critical protein, known as interleukin 11 (IL11), found to be a master driver of fibrosis in heart and kidney failure. The development of first-in-class therapies is underway and can prevent heart and kidney fibrosis and transform treatment for millions of people around the world.

One of the Largest Industry Collaborations in Stem Cell-Based Therapy to Treat Heart Failure and Vision Loss
Duke-NUS and Novo Nordisk, a Danish multinational pharmaceutical company, have come together in one of the largest industry partnerships in the school’s history, to develop a novel system to treat two chronic conditions - cardiomyopathy and macular degeneration.

Alzheimer’s Discovery Could Lead to Different Clinical Approaches
A new study by Duke-NUS and the NUS Yong Loo Lin School of Medicine has found that there are likely differences in the underlying pathology for Alzheimer’s and cerebrovascular disease. This finding may greatly improve the ways in which doctors diagnose, treat, manage and anticipate the outcomes of treatments in patients with neurodegenerative disorders like Alzheimer’s.

Achieving a World’s First to Crack the Durian Genome
Duke-NUS and the National Cancer Centre Singapore (NCCS) achieved a world’s first by deciphering the complete genetic map of the durian. Based on the newly generated genomic data, the team also studied the evolution of the durian and traced its relationship 65 million years back to the cacao plant, which produces chocolate. The team also discovered the cause of the durian’s notorious smell.
COMPASSION
Often, in the world of basic and clinical science, discoveries that might have changed patients’ lives remain undeveloped, or are developed in ways that do not support effective commercialisation. We are determined to change this at Duke-NUS as we train clinicians, clinician researchers and support the development of outstanding healthcare innovators who positively impact and transform the faces of care. We do this by optimising the research conducted through our various programmes, institutes, collaborations and translating discoveries, innovations into commercial applications that can improve healthcare and better patients’ lives. This is conducted under the guidance of our Centre for Technology and Development (CTeD), under the Office of Innovation and Entrepreneurship.

**Translating Research Outcomes Into Impactful Technologies**

**Centre for Technology and Development (CTeD)**

CTeD nurtures, develops and commercialises the intellectual property (IP) of Duke-NUS, and trains biomedical scientists in technology development and conversion of basic research into downstream application.

The Centre connects organisations, technologies and people to facilitate the development of relationships between all of Duke-NUS’ stakeholders. It also provides enterprise support through IP strategy development, lab-based validation, project management, market analysis, team building, project review and brainstorming.

All faculty and staff have access to CTeD and are encouraged to bring early-stage research results and innovative project ideas to the centre for discussion and advice.
The role of CTeD

- Laboratory-based translational research in collaboration with Duke-NUS and SingHealth faculty
- Innovation evaluation and intellectual property assessment and management
- Technology development, incubation and licensing
- Entrepreneur mentorship and company incubation
- Partnering with SingHealth Office of Intellectual Property to commercialise jointly owned IP through the Joint Centre for Technology and Development (J-CTeD)

Partner Organisations

- A*STAR ETPL
- Duke Fuqua School of Business
- Duke Innovation & Entrepreneurship
- Duke Office of Licensing & Ventures
- National Health Innovation Centre
- NTUitive
- NUS Industry Liaison Office
- SingHealth Office of Intellectual Property
- Singapore-MIT Alliance for Research and Technology
- Singapore Eye Research Institute

Successful start-ups from CTeD
128 patents filed

18 licences awarded

48 patents granted

14 spin-offs

136 new invention disclosures

Started up by Duke-NUS investigators
### Protecting Our Intellectual Property

To nurture our innovators, foster an innovation ecosystem and ensure optimal commercial outcomes for Duke-NUS inventions, we have established the Office of Innovation and Entrepreneurship to manage intellectual property (IP) generated by Duke-NUS faculty.

<table>
<thead>
<tr>
<th>Technologies Successfully Listed</th>
<th>Technologies Available for Licensing</th>
<th>Technologies in Process of Development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nutrition</strong></td>
<td><strong>Therapeutics</strong></td>
<td><strong>Therapeutics</strong></td>
</tr>
<tr>
<td>• LPC – Formulations</td>
<td>• WARS2 Therapeutic Agent</td>
<td>• LPC – Delivery Across BBB</td>
</tr>
<tr>
<td><strong>Diagnostics</strong></td>
<td>• Development of Live Attenuated Viruses</td>
<td>• Anti-Cancer Drug Candidate (a131)</td>
</tr>
<tr>
<td>• LPC - Diagnostics</td>
<td>• Calcium/Glut Inhibition Combination</td>
<td>• Chemoprotection</td>
</tr>
<tr>
<td><strong>Education</strong></td>
<td>• Anti-inflammation in Eye</td>
<td>• HSPC Expansion</td>
</tr>
<tr>
<td>• Optimised Learning: CognaLearn</td>
<td></td>
<td>• Laminin Platform Development</td>
</tr>
<tr>
<td><strong>Healthcare Information Technologies</strong></td>
<td></td>
<td>• Laminin: Keratinocytes for Burns</td>
</tr>
<tr>
<td>• Healthcare Monitoring: DataTreats</td>
<td></td>
<td>• Laminin: Pancreatic Islets Expansion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Laminin: Endothelial Cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Diagnostics</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pupillometer Device for Glaucoma Dx</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Wnt Companion Diagnostics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sleep Scoring</td>
</tr>
</tbody>
</table>
COLLABORATION
A WINNING COLLABORATION IN ACADEMIC MEDICINE

Professor Thomas M. Coffman, Dean of Duke-NUS Medical School and Professor Ivy Ng, Group Chief Executive Officer of SingHealth.
Our strategic partnership in Academic Medicine with SingHealth provides opportunities for our students to learn and experience new and current therapies, to contribute and participate in research, and to practise their skills in real clinical settings in SingHealth institutions, where our staff and students have access to state-of-the-art facilities as well as inter-professional learning.

This partnership allows us to harness the collective strengths of Duke-NUS’ medical education and research capabilities as well as SingHealth’s clinical expertise, in order to address healthcare challenges, push boundaries to set new standards of care, transform medicine and improve lives.

We are proud of the many initiatives our collaboration with SingHealth has fuelled – from ground-breaking research studies and joint institutes, to innovative care models.
Focussing on specialities - Academic Clinical Programme

The Academic Clinical Programme is an integrated framework designed to support our vision for Academic Medicine. To create greater synergy in clinical care, education and research, we have harnessed the expertise of 15 clinical disciplines across Duke-NUS and SingHealth to develop the following academic clinical programmes.
The Academic Medical Centre exemplifies our shared goals of delivering world-class education and pioneering research that transform medicine and improve lives.
The SingHealth Duke-NUS Disease Centres focus on disease-based outcomes that will benefit from an integrated care approach. Rather than visiting multiple institutions, patients are able to receive holistic care through a broad base of healthcare professionals in one campus to deliver integrative multidisciplinary care for patients. These centres facilitate deep and targeted ongoing research and education collaborations.

- SingHealth Duke-NUS Blood Cancer Centre
- SingHealth Duke-NUS Breast Centre
- SingHealth Duke-NUS Diabetes Centre
- SingHealth Duke-NUS Head & Neck Centre
- SingHealth Duke-NUS Liver Transplant Centre
- SingHealth Duke-NUS Lung Centre
- SingHealth Duke-NUS Sleep Centre
- SingHealth Duke-NUS Sports & Exercise Medicine Centre
Stronger Together - SingHealth Duke-NUS Joint Institutes & Centres

We have strengthened the capabilities of the SingHealth Duke-NUS Academic Medical Centre with the establishment of joint institutes and centres, each with a focus on specific aspects of medical research.
Philanthropic funding plays an important role in what we do at Duke-NUS. Our visionary benefactors propel our life-saving research in a wide range of diseases. These gracious and generous donations enable our discoveries that enhance and transform medical treatments for patients.

The unwavering contributions we receive also help to lift our students’ financial burdens so that they can focus on their medical education and have access to advanced facilities and equipment. The fruits of these efforts are borne through the talent and resources that strive to benefit needy communities in Singapore and around the region.

Every contribution combines to make a significant and immediate impact to improving medicine and lives of tomorrow.
Mohamad Fadhli bin Masri  
MD-PhD candidate, Class of 2020  
*Shaw Foundation Scholarship Recipient*

Mohamad Fadhli bin Masri is a firm believer that giving back and paying forward lead to positive outcomes for both immediate and future generations. Grateful for the scholarship and aware of his responsibilities as an awardee, he is committed to helping and inspiring those around him and those who come after him.

Never one to accept second best, Fadhli is set on exceeding the expectations of the clinical and scientific communities he works within. To stay the course, he constantly reminds himself that he chose his path so that he could play a role in improving patient care.

Zhou Qian Sophie  
MD Graduate, Class of 2018  
*Goh Foundation Scholarship Recipient*

A recent graduate of Duke-NUS, Sophie is currently assessing the opportunities that her degree has opened up for her. While she takes a holistic view of healthcare, she has been inspired by her clerkship experiences to pursue Family Medicine. For Sophie, this is a natural choice. As someone who enjoys meeting people and is a good listener and a loyal confidant, she is destined to make a people-oriented, professional and empathetic doctor who will enjoy success in every aspect of patient care.
Dr Lynn Yap
Recipient of Khoo Postdoctoral Fellowship Award

“The Khoo Postdoctoral Fellowship enabled me to perform state-of-the-art RNA sequencing techniques and better understand how cardiac laminin supports cardiovascular progenitor cell generation and the therapeutic effects of these cells in treating heart failure. These discoveries led to in vivo mouse studies that showed that progenitor cells are able to repair a damaged heart effectively. As a result, multinational pharmaceutical company Novo Nordisk has invested S$2 million into our research and development with the goal to achieve clinical grade cells for first-in-man clinical trials within the next few years.”

Ms Goh Sok Hong
Senior Associate Director,
Office of Education
Donor to Class Gift of 2018, Student Financial Aid and Project DOVE

“I believe that we receive more blessings when we give rather than receive, and that whatever we take from the community, it is our duty to give back. I hope all of our students are able to pursue their studies without having to worry about finances. I’m especially inspired by our students’ enthusiasm to want to help people through our community projects.”
**Project DOVE**

Founded in 2010, Project DOVE (Duke-NUS Overseas Volunteering Expedition) is an annual student-led initiative that provides medical help to underprivileged communities overseas, at the same time improving our students’ clinical skills as they train as volunteer doctors treating patient diseases. Through serving the local community and building relationships, students learn the value of public health approaches in creating sustainable change.

**Camp Simba**

Camp Simba, an initiative started by students from Duke-NUS and NUS Yong Loo Lin School of Medicine, stepped into its 10th year in 2018. The camp aims to address the emotional needs of children whose family members are afflicted with cancer. With family members struggling to cope with their illnesses, these children are often left to deal with the large changes within their family on their own and may miss out on the simple joys of childhood. Our students play a part in ensuring that the camp builds a community where these children can draw support and strength from one another through shared experiences.
GOVERNING BOARD

CHAIRMAN

MR KAI NARGOLWALA
Chairman of Executive Committee, Member of Audit Committee and Finance & Investment Committee

DEPUTY CHAIRMAN

PROFESSOR HO TECK HUA
Senior Deputy President and Provost National University of Singapore
Deputy Chairman of Executive Committee and Chairman of Academic & Research Committee

MEMBERS

PROFESSOR EDWARD G. BUCKLEY
Vice Dean for Education
Chair, Department of Ophthalmology
Vice Chancellor for Duke-NUS Affairs
Duke University School of Medicine
Co-Chairman of Academic & Research Committee and Member of Executive Committee

DR NOELEEN HEYZER
Social Scientist and Former United Nations Under-Secretary-General
Development Committee

MRS QUEK BIN HWEE
Independent Non-Executive Director The Hongkong and Shanghai Banking Corporation Limited
Executive Committee and Chairman of Audit Committee

MS TEO SWEE LIAN
Non-Executive and Independent Director Singapore Telecommunications Ltd
Audit Committee

MR ALVIN LIM
Director (International Directorate) Ministry of Finance
Audit Committee and Finance & Investment Committee
DR GEH MIN
Ophthalmologist, Eye Clinic & Surgery
Immediate Past President
Nature Society (Singapore)
Former Nominated Member of Parliament

PROFESSOR RAJ MOHAN NAMBIAR
Visiting Consultant Surgeon
(Singapore General Hospital, Khoo Teck Puat
Hospital & Tan Tock Seng Hospital)
Emeritus Consultant, Changi General Hospital
Senior Consultant, Ministry of Health
Academic & Research Committee

PROFESSOR IVY NG
Group Chief Executive Officer
Singapore Health Services Pte Ltd
Executive Committee, Academic & Research
Committee and Development Committee

ASSOCIATE PROFESSOR BENJAMIN ONG
Director of Medical Services
Ministry of Health
Academic & Research Committee

MR LEE MING SAN
Managing Director
One North Capital Pte Ltd
Executive Committee, and Chairman of Finance
& Investment Committee and Development Committee

MR LEE KIM SHIN
Managing Partner
Allen & Gledhill LLP
Audit Committee

PROFESSOR HSIEH TSUN-YAN
Chairman and Lead Counselor
LinHart Group
Development Committee

MR ONG TZE-CH’IN
Coordinating Divisional Director
Higher Education Group
Ministry of Education
Executive Committee and Academic & Research
Committee

PROFESSOR A. EUGENE WASHINGTON
Chancellor for Health Affairs
Duke University
President and CEO
Duke University Health System
Executive Committee and Academic & Research
Committee
SENIOR MANAGEMENT

PROFESSOR THOMAS M. COFFMAN
MD
Dean
Professor, Cardiovascular & Metabolic Disorders Programme
Other Affiliations:
James R. Clapp Professor of Medicine, Duke University Medical Centre
Director, Cardiovascular Research Centre, Duke School of Medicine

PROFESSOR PATRICK J. CASEY
PhD
Senior Vice Dean, Research
Professor, Cancer & Stem Cell Biology Programme
Other Affiliations:
James B. Duke Professor of Pharmacology & Cancer Biology
Professor of Biochemistry
Duke University Medical Centre

MS KAREN CHANG
Senior Vice Dean
Group Director, Corporate Services

PROFESSOR IAN CURRAN
BSc, AKC, MBBS, FRCA, Pg Dip Med Ed (distinction), FFPMRCA, FAcadMEd, FSSH
Vice Dean, Education
Co-Director, Academic Medicine Education Institute (AM•EI)

PROFESSOR WONG TIEN YIN
MBBS, MMED (Ophth), MPH, PHD, FRCSE, FRANZCO, FAMS
Vice Dean, Academic & Clinical Development
Other Affiliations:
Provost’s Chair Professor, National University of Singapore
Medical Director & Senior Consultant
Ophthalmologist, Singapore National Eye Centre
Chair, Ophthalmology and Visual Sciences Academic Clinical Programme
Chairman, Board of Directors, Singapore Eye Research Institute

ASSOCIATE PROFESSOR DAVID M. EPSTEIN
PhD
Vice Dean, Innovation & Entrepreneurship Office of Technology & Development
Associate Professor, Cancer & Stem Cell Biology Programme
Other Affiliations:
Duke University School of Medicine
Duke Institute for Genome Sciences & Policy
Duke-NUS commits to the education of its medical students and to help fund promising research and education programmes to find cures, transform medicine and improve lives.

To find out how you can support the Duke-NUS Medical School in shaping the future of healthcare, please contact:

**Duke-NUS Communications & Development**

8 College Road, Level 6  
Singapore 169857

**Email:** development@duke-nus.edu.sg  
**Web:** www.duke-nus.edu.sg/giving